Stockscreener 앱 받기
7.47
0.27%
0.02
시간 외 거래:
7.33
-0.14
-1.87%
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Millennium Management LLC Reduces Stake in Vanda Pharmaceuticals Inc - GuruFocus
VNDA: Imminent launches and label expansions position the portfolio for major near-term growth - TradingView — Track All Markets
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - Chartmill
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Down 52.3% in December - MarketBeat
Loss Report: How Vanda Pharmaceuticals Inc stock benefits from tech adoptionShort Setup & Weekly High Potential Alerts - Bộ Nội Vụ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - FinancialContent
Revenue Check: Why Vanda Pharmaceuticals Inc stock remains a top recommendationPortfolio Gains Summary & Fast Gain Stock Tips - Bộ Nội Vụ
Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Finviz
Retail Trends: Will Vanda Pharmaceuticals Inc stock attract more institutional investorsProfit Target & Technical Confirmation Trade Alerts - Bộ Nội Vụ
Aug Retail: Why Vanda Pharmaceuticals Inc stock remains a top recommendation2025 Technical Overview & Weekly Consistent Profit Watchlists - Bộ Nội Vụ
Published on: 2026-01-12 16:11:40 - Улправда
What sentiment indicators say about Vanda Pharmaceuticals Inc. stockMarket Sentiment Summary & Weekly High Potential Stock Alerts - Улправда
Published on: 2026-01-08 21:09:38 - ulpravda.ru
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder - Sahm
Can Vanda Pharmaceuticals Inc. (VM4) stock surprise markets with earningsJuly 2025 Spike Watch & Reliable Breakout Forecasts - ulpravda.ru
Is Vanda Pharmaceuticals Inc. stock affected by interest rate hikes2025 Historical Comparison & Fast Entry and Exit Trade Plans - ulpravda.ru
Is Vanda Pharmaceuticals Inc. stock positioned well for digital economyEarnings Recap Report & Reliable Entry Point Alerts - ulpravda.ru
Is Vanda Pharmaceuticals Inc. (VM4) stock good for long term investingWeekly Risk Report & Low Drawdown Trading Techniques - ulpravda.ru
Vanda Pharmaceuticals (VNDA) Faces FDA Setback on HETLIOZ Application - GuruFocus
FDA rejects Vanda's jet lag drug application days after approving motion sickness drug - The Business Journals
How Vanda Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Sector Moves & Low Risk High Win Rate Picks - ulpravda.ru
Vanda Pharmaceuticals (VNDA) Faces Setback with FDA Rejection - GuruFocus
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter o - GuruFocus
Vanda falls as FDA rejects jet lag drug (VNDA:NASDAQ) - Seeking Alpha
Vanda Pharmaceuticals (VNDA) Shares Fall After FDA Decision - GuruFocus
Vanda Faces FDA Setback on HETLIOZ Jet Lag Application - TipRanks
Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application - Stocktwits
Vanda Pharmaceuticals stock falls after FDA rejects jet lag treatment application - Investing.com Canada
Vanda Pharmaceuticals Inc Receives FDA Decision on HETLIOZ® sNDA for Jet Lag - TradingView — Track All Markets
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder – Company AnnouncementFT.com - Financial Times
Vanda Pharmaceuticals Inc. (VNDA) Stock Analysis: Evaluating a 59.54% Potential Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews
Vanda Pharma says FDA is in violation of FDCA regarding its Hetlioz sNDA - The Pharma Letter
Q1 EPS Estimate for Vanda Pharmaceuticals Raised by Analyst - MarketBeat
FDA Approves Vanda Pharma Motion Sickness Drug, Fuels Upside - Benzinga
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
HC Wainwright Analysts Raise Earnings Estimates for VNDA - MarketBeat
FDA Grants Approval to Vanda Pharma’s Motion Sickness Medication, Boosting Growth Potential - Bitget
Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness - Yahoo Finance
VIX Spike: Can Vanda Pharmaceuticals Inc VM4 stock surprise markets with earningsJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - moha.gov.vn
VNDA: HC Wainwright & Co. Raises Price Target to $22, Maintains Buy Rating | VNDA Stock News - GuruFocus
Gastric Motility Disorder Drugs Market is expected to reach US$ - openPR.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
US FDA approves Vanda Pharmaceuticals' motion sickness drug - ET Pharma
Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn’t (Rating Downgrade) (VNDA) - Seeking Alpha
Vanda's tradipitant can significantly reduce nausea in those taking a GLP-1 - MSN
Vanda Pharmaceuticals Inc. (VNDA): Investor Outlook on Potential 48.81% Upside Opportunity - DirectorsTalk Interviews
Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review - MSN
Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley - Yahoo Finance
Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus (NASDAQ:VNDA) - Seeking Alpha
After 40 Years, USFDA Approves Vanda Pharma's Motion Sickness Drug Nereus - Medical Dialogues
VNDA obtains FDA nod for motion sickness drug, stock gains - MSN
Vanda wins FDA approval for NEREUS motion sickness drug - MSN
Jefferies Initiates Vanda Pharmaceuticals(VNDA.US) With Hold Rating, Announces Target Price $7.5 - 富途牛牛
Vanda stock jumps with FDA approval of motion sickness drug - BioWorld MedTech
Vanda Pharmaceuticals hits 3-year high after FDA approves Nereus | Tap to know more | Inshorts - Inshorts
4.73%
0.92%
자본화:
|
볼륨(24시간):